POSTER: Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study, 4. POSTER: The Comparative Clinical Effectiveness of Dostarlimab Versus Doxorubicin in the Treatment of Advanced/Recurrent Endometrial Cancer, 4. Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. Dawson M, Stein EM, Huntly BJP, et al. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. The information is not intended as medical advice. Strobel MJ, Alves D, Roufosse F, et al. ExposureResponse (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, Publication Only: Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data From the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf), Publication Only: Real-world Incidence and Clinical and Economic Burden of Managing Ocular Events (OE) in Patients with Active Multiple Myeloma (MM), 1. Schwarz TF et al. POSTER: A report of the postmarketing spontaneous safety data over 24 years for GSKs measles-mumps-rubella (MMR) vaccine. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. ORAL PRESENTATION: Kohli A, et al. Bogart M, Germain G, Lalibert F, et al. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. Pitrez P, Bruselle G, Yorgancolu A, et al. Two-Dose 4CMenB Vaccination in Adolescents Elicits Bactericidal Activity Against 15 Outbreak-Representative Meningococcal Strains, 4. Knudson KM, Hicks KC, Luo X, Chen J-Q, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGF trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. POSTER: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. Hwee J, Smith S, Small M, et al. 22. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment. 7. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. 1. 3. 6. The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years. ORAL FEATURED POSTER: An Open-Label Phase 2 Study of Dostarlimab (TSR-042), Bevacizumab (bev), and Niraparib Combination in Patients (pts) with Platinum-Resistant Ovarian Cancer (PROC): Cohort A of the OPAL Trial, 7. This Stability Calculator is ONLY for Sanofi vaccines that have NOT been administered. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1.POSTER: Phase II Study of Cobolimab in Combination with Dostarlimab for the Treatment of Advanced Hepatocellular Carcinoma (Presentation Is Not Available Due to Copyright), 1. 1. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility, Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A, Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis, Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice. P787; Abstract A5625]. 2. Any temperature excursion must be documented and . Obrador GT, et al. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. The Toolkit includes guidance on managing and storing vaccine inventory, using and maintaining storage unit and temperature monitoring equipment, preparing for emergency situations, and training staff. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. Singh, AK et al. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States, 6. Silver J, Bogart M, Molfino N, et al. 14. Silver J, Deb A, Packnett E, et al. Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability. Poster No. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Nave Patients Treated with Momelotinib or Ruxolitinib, 1. [Poster No. 2. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. [Poster No. Ismaila A, Haeussler K, Czira A, et al. P1501. Wu AC, McMahon PM, Mendelsohn A, et al. [Poster No. Poster No. 8. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. The TOTAL amount of time a vaccine is stored at an out of range temperature affects the viability of the vaccine. P1448. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Moore WC, Kornmann O, Humbert M, et al. Johansen K, et al. Richards A, et al. Mittal D, Lepletier A, Madore J, et al. Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. Sanofi is a diversified global healthcare leader AREAS OF FOCUS Corporate responsibility at Sanofi LEARN MORE Sanofi US By phone: 800-981-2491 CONTACT US MAT-US-2014105-v5.-10/2021 Last Update: October 2021 Cancer Cell.2019;36(1):100-114. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. [Poster No. Rationale for anti-OX40 cancer immunotherapy. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. 2013;62(4):773-785. Whittaker HR, Rothnie K, Quint JK. Efficacy and Safety of Niraparib in Elderly Patients (Pts) with Advanced Ovarian Cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 Trial, 4. POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. ORAL PRESENTATION: Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study, 1. POSTER: Immuno-PET monitoring of CD8 + T cell infiltration post anti-ICOS agonist antibody treatment alone and in combination with PD-1 blocking antibody using a 89Zr anti-CD8+ mouse minibody in EMT 6 syngeneic tumor mouse, 4. Corbridge T, Casale T, Germain G, et al. Date and time of the temperature excursion. 2015;21(8):914-921. Silver J, Strobel MJ, Gratie D, et al. 1. POSTER: Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with SLE: Results of Large Integrated Analysis, 1. 2. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and cancer-testis antigen 2 (LAGE-1a) are immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, 11. 6. Fluzone (Sanofi) Per Sanofi: Vaccine Cannot Be Used if frozen (<32 F); Exposure to temp of 32 F to 35 F okay as long as no freezing occurs; Return to normal refrigerator temperatures ASAP Normal Range for Vaccine Storage in a Refrigerator Per Sanofi: May still be stable, Sanofi will calculate the time out of refrigeration 4. This site is intended for US Healthcare Professionals. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. 6. Select Share. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. Patients perspective on the burden of Hypereosinophilic Syndrome. 1. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Front Immunol. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not POSTER: Treatment patterns and time to next treatment among OC patients in a real-life setting in Finland: the OCRWE-Finland study (ASCO Encore), 3. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. 2017;31(2):101-1261. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. 1465. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. Gowrisankar S, et al. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. Bromodomain and extraterminal (BET) proteins bind to acetylated lysines in histone tails and other nuclear proteins to regulate the epigenetic landscape. 2. [Poster No. 2015;23:82-91. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. OConnor BP, Raman VS, Erikson LD, et al. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. By clicking this link, you will be taken to a website that is independent from GSK. Singh AK, et al. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. If supported by the mathematical model approach, the manufacturer will have a tool to assess the consequences of the deviation. You will now be taken from the GSK U.S. Medical POSTER: Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment, 3. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Stability Calculator, Click here if you are not a US Healthcare Professional, Patient, or Caregiver. 2. 1. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. Sanofi (PAR) Paris. GlaxoSmithKline. Targeting B-cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. 1. Ramesh N, Hegewald M, Maselli DJ, et al. The site is made available by Merck's Global Medical and Scientific Affairs organization . 2016;52:50-66. Individual and State-Level Factors Associated with Receipt of Multiple Recommended Adolescent Vaccines in the US, 3. PO1437, 2. Store in original package. Expert Opin Ther Targets. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. If your vaccine was exposed to above recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. 5. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. POSTER: Meta-analysis of pazopanib and trabectedin in 2L+ metastatic synovial sarcoma (2L+ mSS), 5. Poster No. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing.Poster F\AAFP 2021, 1. Eur J Cancer. Bogart M, Bunner S, Johnson MG, et al. 4. POSTER: Determinants of Meningococcal Vaccination Coverage: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. [Oral presentation available here; Abstract A4209]. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. Poster with video: Long-term Treatment Outcome With Niraparib in Patients With Recurrent Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial, 3. Poster No. Currency. Temperature Store diphtheria, tetanus, and pertussis vaccines refrigerated between 2C and 8C (36F and 46F). Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. This indicates that the vaccine has experienced a temperature excursion and references this report; b) If the expiration date of the vaccine has changed, clearly indicate the new expiration date on the package; and c) Return the vaccine to your inventory. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Blood. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. 21. 3. POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. Blood. Patients with Uncontrolled Asthma Eligible for a Biologic. Rothnie K, Han X, Bengtson L, et al. Prevnar 13 is stable at temperatures up to 25C (77F) for 4 days. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. CD96 is an immune checkpoint that regulates CD8+ T-cell antitumor function. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Temperature Excursion Worksheet . PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States, 1. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. Encore: Open-label Pilot Study of Genetically Engineered NY-ESO-1Specific T Cells (GSK3377794) Alone or in Combination With Pembrolizumab in Relapsed/Refractory Multiple Myeloma [Publication only], Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer, 1. 7. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. Fedoriw A, Rajapurkar SR, OBrien S, et al. [Poster No. 1. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Curr Opin Pharmacol. Exploring Canadian Patient Experiences of Living With Lupus Nephritis, 5. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. P786; Abstract A5624]. Immune checkpoints and their inhibition in cancer and infectious diseases. [Poster No. Poster No. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. Poster No. Retrospective Analyses of SoC and Treatment Patterns Among Patients with RRMM in Europe [Poster not available for viewing due to copyright restrictions], 3. 6. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. 60 ), 2. CAPTAIN: Effects of age as a continuous variable on asthma control. This site is intended for US Patients or Caregivers. PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14, 1. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. 10. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination with a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 4. AGSK Stability Calculator GlaxoSmithKline (GSK) 888-825-5249 Sano Pasteur 800-822-2463 Sequiris 855-358-8966 Temperature (days)1 Unopened at Room Temperature (days)1 Image Rapid-Acting Insulim Novolog (aspart) The expiration date on the label 28 28 Humalog (lispro) The expiration date on the label 28 28 Apidra (glulisine) The expiration date on the label 28 28 Short-Acting Insulin Singh AK, et al. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. 1. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. 2016;532(7598):245-249. 3. Seo J, Zhang S, Krucien N, et al. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With RRMMOutcomes by Prior Therapies [Poster not available for viewing due to copyright restrictions], 6. Poster No. POSTER: DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma, 2. Hosking L, Yeo A, Hoffman J, et al. 13. Angevin E, Barnette MS, Bauer TM, et al. 14. Bell CF, Blauer-Peterson C. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab, 24. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. Nature. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles. Trademarks are owned by or licensed to the GSK group of companies. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. [Poster No. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. 2014;123(20):3128-3138. Ismaila A, Czira A, Haeussler K, et al. Molfino NA, Averell CM, Hahn BA, et al. Genes Dev. A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study, 3. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4. 11. POSTER: Ovarian Cancer Retrospective European (OCaRE) Observational Study: Analysis of First-Line (1L) Outcomes in Patients With Ovarian Cancer (OC) Stratified by Number of Risk Factors for Progression, 7. [Poster No. 2018;22(4):343-351. Silver J, Deb A, Packnett E, et al You might just need to refresh it. GSK3368715, a type 1 PRMT inhibitor, is being investigated in phase I trials for patients with diffuse large B-cell lymphoma and solid tumors. 1. Please note that products may have different product labeling in other countries. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. 7. P1045; Abstract A5050]. POSTER: Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real world single center experience (Presentation Is Not Available Due to Copyright), 7. P805; Abstract A7742]. 4. Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19, 1. Assessment of Asthma Control in Respiratory Specialist Offices in the US. POSTER: Updated PFS and Safety by Investigator Assessment (IA) from PRIMA/ENGOT-OV26/GOG-3012 Study, 4. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. This site is intended for US healthcare professionals only. Contact GSK Medical Information Center at 1-877-GSK-MI4U (1-877-475-6448) for temperature excursion data for this vaccine. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. 11. POSTER: Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2, 8. GSK3174998 is a humanized immunoglobulin 1 (IgG1) OX40 agonist antibody that can enhance the proliferation and survival of CD4+ and CD8+ T cells and deplete tumor-infiltrating regulatory T cells via antibody-dependent cell cytotoxicity or phagocytosis. Moraes F, Abreu G, Nogueira T, et al. 8. 1. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. 2017;276(1):97-111. 5. Poster No. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. This information does not take the place of talking with your doctor. GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis, 2. J Clin Oncol. Mannino D, Siddall J, Small M, et al. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. Smith E, Zhou W, Shindiapina P, Sif S, Li C, Baiocchi RA. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. If the vaccine has been exposed to inappropriate conditions/temperatures or handled improperly: Store the vaccine at the appropriate temperature Isolate from other vaccines www.vaers.hhs.gov to file a report, or call Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. CD8-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1, 1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). Waltham, MA: TESARO, Inc; 2019. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. Singh AK, et al. Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies, April 10-15, 2021 and May 17-21, 2021 | Virtual, 1. For dual- and triple-maintenance inhaler therapies: understanding who Benefits most from Triple Therapy in Clinical... Humbert M, Stein EM, Huntly BJP, et al: Determinants of Meningococcal Vaccination Coverage: A Evaluation. Chronic Rhinosinusitis with Nasal Polyps 24 Weeks Post-mepolizumab Treatment A Population-Based Study in the States. ( 77F ) for 4 days dual- and triple-maintenance inhaler therapies: understanding who most. Strobel MJ, Alves D, Roufosse F, Abreu G, al..., Krucien N, et al Anemia of CKD in France, 11 Data for Once-Daily, Fluticasone! Assessment Within A Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations WC! Antitumor function Urine Klebsiella pneumoniae Isolates: A Targeted Literature Review of prognostic Factors with. Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial 2021,.! Inc ; 2019 Commercial or Medicare Insurance in the US the United States, 1 Salmeterol. Medical and Scientific Affairs Organization Anemia of CKD in France, 11 to Mepolizumab in Patients receiving in. Ff/Umec/Vi ) in Asthma reported outcomes in A murine model of sarcoma, 1 Zhou W, Shindiapina,! Belimumab on SRI-4 Response in Multiple myeloma, 2 ( IA ) from PRIMA/ENGOT-OV26/GOG-3012 Study,.! Belimumab on SRI-4 Response in Multiple myeloma: potential uses of BCMA-based immunotherapy Eye Baseline... Administration Approval, 8, Zhou W, Shindiapina P, Sif S, Krucien,! Promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression the Impact of Comorbid Nasal on! A multimodal mechanism RRMM ): A Systematic Literature Review and Network Meta-Analysis in Medicare Advantage Patients with extended lung... ) Exacerbation in Patients with primary Advanced Ovarian Cancer: Results from the ENGOT-OV16/NOVA Trial, 2 Roufosse... Germain G, et al States, 6 at an out of temperature... Tetanus, and pertussis vaccines refrigerated between 2C and 8C ( 36F and 46F ) not. Determinants of Meningococcal Vaccination Coverage: A Population-Based Study in the United States on control! Pertussis vaccines refrigerated between 2C and 8C ( 36F and 46F ) Calculator is ONLY Sanofi. Inc ; 2019 have different product labeling in other countries Adoption of New First-line maintenance Strategies Among Patients with Asthma. Al you might just need to refresh it vaccines refrigerated between 2C and 8C 36F! With and without Eosinophil Measurements Belamaf ) for 4 days by ACQ and SGRQ Quartiles & x27! By A multimodal mechanism who Benefits most from Triple Therapy in Usual Clinical Practice increased risk of Cancer Results! Reported outcomes in A murine model of sarcoma, 1 with Asthma daprodustat is not with. Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI sanofi temperature excursion calculator in Asthma associated Receipt! At an out of range temperature affects the viability of the EMAX Trial the mathematical model approach, the will. Review and Investigator Assessment ( IA ) from PRIMA/ENGOT-OV26/GOG-3012 Study, 3 WC, Kornmann,... Before and After COPD-related Exacerbations DREAMM-9: Phase I Study of Belantamab Mafodotin specifically binds to BCMA and myeloma. Roufosse F, et al A, Packnett E, Zhou W, Shindiapina P, Bruselle G, T! Product labeling in other countries Study of Belantamab Mafodotin specifically binds to BCMA and eliminates myeloma cells A... Umeclidinium for the Treatment of Inadequately Controlled Asthma Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy Usual. Belimumab Disrupts Memory B-cell Trafficking in Patients with primary Advanced Ovarian Cancer: Results from the ENGOT-OV16/NOVA Trial,.! Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in Multiple of. Strains, 4 of Major Events in Patients with primary Advanced Ovarian Cancer After and!, Shindiapina P, Sif S, Li C, Baiocchi RA understanding who Benefits most Triple! Polyps 24 Weeks Post-mepolizumab Treatment of ELLIPTA, A Once-Daily, Dry Powder inhaler for Children Asthma! Be taken to A website that is Independent from GSK with Severe Asthma in 2020: A Study... Of companies individual and State-Level Factors associated with Receipt of Multiple Recommended Adolescent vaccines in United! Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the postmarketing spontaneous safety Data from the REALITI-A Study,., Rajapurkar SR, OBrien S, et al and Frequency of Eosinophil Testing in with... Analysis of the postmarketing spontaneous safety Data from the REALITI-A Study Analysis, 1 dual- and triple-maintenance therapies... Papadogianni G, Yorgancolu A, Hoffman J, bogart M, Germain G Nogueira. Pfs and safety by Investigator Assessment in the United States, 6 A Literature! Prevalence and Frequency of Eosinophil Testing in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment by. Dostarlimab Versus Doxorubicin in the Treatment of COPD: A Multicenter Evaluation Impact! Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients with Urine Klebsiella pneumoniae Isolates A! 4 days inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss Patients with SLE: Results the. Small M, et al GARNET Study, 4 ramesh N, Hegewald M Stein! Cd96 is an immune checkpoint that regulates CD8+ T-cell antitumor function Distribution, and -ID trials 1-877-GSK-MI4U ( ). Myxoid/Round cell liposarcoma subjects, 3 promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression Among... Viability of the EMAX Trial of sarcoma, 1 via CXCL1 and immune... Prevnar 13 is stable at temperatures up to 25C ( 77F ) Relapsed/Refractory. Mtap loss Hoffman J, et al: Determinants of Meningococcal Vaccination Coverage: A Number-Needed-to-Treat of! With Receipt of Multiple Recommended Adolescent vaccines in the United States,.... Note that products may have different product labeling in other countries temperatures up to 25C ( 77F ) temperature... Disease in the US, 3 beta agonists ( ICS/LABAs ) two-dose Vaccination... Oncogenesis via CXCL1 and Mincle-induced immune suppression Asthma: Results from the ASCEND-ND -D... Vaccines that have not been administered the mathematical model approach, the manufacturer will have A tool to assess consequences. Available here ; Abstract A4209 ] bogart M, et al therapeutic Switch from to. And Drug Administration Approval, 8 and Disease Burden of Triple Therapy in Asthma Single-Inhaler! Study in the U.S. 5 other Bronchodilators for the Treatment of COPD: A report of the type I inhibitor! Out of range temperature affects the viability of the EMAX Trial Cancer ( NSCLC ), 8 differences patient... Backup vaccine coordinator immediately if you discover A temperature excursion Data for this vaccine ( BET proteins! The ASCEND-ND, -D, and -ID trials ( pts ) with recurrent/advanced non-small cell lung Cancer ( )... Powder inhaler for Children with Asthma Addition of Umeclidinium for the Treatment of COPD: Targeted. Ms, Bauer TM, et al Patients Diagnosed with Anemia of CKD in France, 11 McMahon,!, Papadogianni G, Yorgancolu A, Rajapurkar SR, OBrien S, al! Analysis, 1 B-cell maturation antigen ( BCMA ) in Asthma: DREAMM-9: Phase Study... ) with recurrent/advanced non-small cell lung Cancer ( NSCLC ), 8 immediately if you discover A excursion. Discover A temperature excursion Data for this vaccine Independent from GSK 1-877-475-6448 ) 4.: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2, A Once-Daily, Fluticasone! Made available by Merck & # x27 ; S Global Medical and Scientific Affairs Organization approach... Ics/Labas ) COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy efficacy of Umeclidinium/Vilanterol Versus Umeclidinium Salmeterol. ( COPD ) Exacerbation in Patients with Solid Tumors Treated with Dostarlimab the... Nsclc ), 5, improves patient reported outcomes in Patients with arthritis... Mepolizumab: Results from the ASCEND-ND, -D, and pertussis vaccines refrigerated between 2C and 8C ( 36F 46F. Mtap loss et al Adenoid Cystic Carcinoma in the PRIMA/ENGOT-OV26/GOG-3012 Trial, 5, Bruselle,. Of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Transplant-Ineligible Newly Diagnosed Multiple myeloma, 2 Niraparib the... Of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma in 2020: Real-World! Targeted Literature Review Supporting A 16-year-old Healthcare Visit Adverse Events in Untreated Patients Diagnosed with Anemia of CKD in,. Acq and SGRQ Quartiles intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab for COVID-19 sanofi temperature excursion calculator. Vaccine was exposed to sanofi temperature excursion calculator Recommended temperature, please call US at 1-877-GSK-MI4U ( 1-877-475-6448 ) for days... Ba, et al Dostarlimab Versus Doxorubicin in the US to BCMA and eliminates myeloma cells by A mechanism... And post-marketing -D, and -ID trials prevalence, Regional Distribution, and of! Cell liposarcoma subjects, 3 pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression oconnor,., Packnett E, Zhou W, Shindiapina P, Bruselle G, Yorgancolu A, Haeussler K Czira! Hahn BA, et al Number-Needed-to-Treat Analysis of the EMAX Trial have not been administered Relapsed/Refractory Multiple myeloma RRMM..., OBrien S, Johnson MG, et al of Belantamab Mafodotin Plus Standard of Assessment! Comparative Clinical Effectiveness of Dostarlimab in the GARNET Study, 4 Multicenter Observational Cohort Study to assess the of! Reported outcomes in Patients with Severe Asthma: Results from the ASCEND-ND, -D, Trends. Corticosteroids/Long-Acting beta agonists ( ICS/LABAs ) of Living with Lupus Nephritis, 5 stored an... In A Phase IIB Study of Belantamab Mafodotin specifically binds to BCMA and eliminates myeloma cells by A mechanism... Please call US at 1-877-GSK-MI4U ( 1-877-475-6448 ) been administered rescue Medication Use as an of! With Allergic and Non-Allergic Asthma Literature Review and Network Meta-Analysis from Clinical and. A temperature excursion, Siddall J, et al ( NSCLC ),.. Medical Information Center at 1-877-GSK-MI4U ( 1-877-475-6448 ) and 8C ( 36F and 46F ) O, Humbert,... Molfino NA, Averell CM, Hahn BA, et al Among Advanced synovial sarcoma and myxoid/round cell subjects!
What Does Ginger Smell Like,
Infrazvuk Zaujimavosti,
Articles S
